Condition category
Circulatory System
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Stroke is a leading cause of death and disability worldwide, and is the third highest cause of death in Taiwan. About 85% of strokes are ischemic strokes. Ischemic strokes happen when the arteries that supply the brain with oxygen (the carotid arteries) become narrowed (stenosis) or blocked (occluded) by a sticky substance called plaque that builds up on the artery walls (atherosclerosis), causing reduced blood flow (ischemia) to the brain. Atherosclerosis in the carotid arteries is one of the biggest causes of recurrent stroke, and so reducing carotid stenosis is an important part of stroke prevention. There is growing evidence that stem cell therapy using endothelial progenitor cells (EPCs) (stem cells from bone marrow) can help to regenerate the lining of blood vessels. Previous studies have shown that increasing levels of EPCs circulating in the blood is related to improvement in the recovery of those with ischemic stroke. Currently, there is little research looking at the safety and effectiveness of using EPC therapy for treating ischemic stroke. The aim of this study is to find out whether ECP therapy is an effective treatment for patients with brain ischemia following an ischemic stroke.

Who can participate?
Adults aged between 45 and 80 who had an ischaemic stroke at least six months ago.

What does the study involve?
All participants receive eight injections of granulocyte-colony stimulating factor (a protein which stimulates the bone marrow to produce stem cells and release them into the bloodstream) every 12 hours for four days. On the fifth day, patients have a tube placed into the right femoral vein (main vein in the thigh) so that circulating EPCs can be collected. These EPCs are then injected back into the patients into the internal carotid artery (in the neck). Patients are then followed up for five years through a combination of interviews and medical record reviews, in order to find out how effective the treatment has been.

What are the possible benefits and risks of participating?
Participants may benefit from improvement to their disability. There are risks of side effects from the EPC therapy, including deterioration of brain function, recurrent stroke, heart problems, blockage of arteries, bleeding, anemia, deterioration of kidney function, gastrointestinal (gut) complications, electrolyte (minerals in the body) imbalance, sepsis (blood poisoning) and cancer.

Where is the study run from?
Kaohsiung Chang Gung Memorial Hospital (Taiwan)

When is the study starting and how long is it expected to run for?
January 2014 to June 2024

Who is funding the study?
National Science Council (Taiwan)

Who is the main contact?
Dr Hon-Kan Yip

Trial website

Contact information



Primary contact

Dr Hon-Kan Yip


Contact details

University College of Medicine
Ta Pei Road Niao Sung District
Kaohsiung City
+886 7 7317123 ext. 8300

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Autologous intra-carotid arterial transfusion of peripheral blood stem cells (PBSC) improves brain ischemia and reperfusion – A safety and tolerability study


Study hypothesis

Peripheral Blood Stem Cells transplantation for the patients with brain ischemia may be a more effective therapy than traditional drug therapy.

Ethics approval

Chang Gung Memorial Hospital, 24/11/2015, ref: 104-6798C

Study design

Prospective single-centre non-randomised study

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet

No specific participant information sheet available, please use the contact details below to request a further information.


Chronic ischemic stroke


All participants receive eight granulocyte-colony stimulating factor (G-CSF) injections of 5 μg/kg sc q12h over a course of four days after admission and endothelial progenitor cell (EPC) collection at day 5 for 3 hours from double lumen sheath inserted from right femoral vein using a machine (COBE Spectra 6.1). The collected EPC will be immediately transfused back to patients themselves with a dose of 3x10(7) EPC once through internal carotid artery of infarct side using a 6F JR catheter through left radial arterial sheath. The participants will be followed up at Neurology and Cardiovascular outpatients clinic for safety and efficacy monitoring for 5 years.

Intervention type



Drug names

Primary outcome measure

Safety and tolerability of intracarotid artery autologous endothelial progenitor cells injection is measured through patient interviews and reviewing medical records throughout the five years of the study

Secondary outcome measures

1. Recurrent stroke or death rate is measured by reviewing medical records at 90 days
2. Disability is measured using the modified Rankin Scale score, Barthel Index WAIS-III and CASI National Institutes of Health Stroke Scale (NIHSS) at 24 hours, 72 hours, 30 days and 90 days
3. Brain reperfusion status is measured using Magnetic resonance imaging (Arterial Spin Labeling (ASL) and Dynamic Contrast Enhancement) at 24-72 hours post-therapy and 90 days
4. Brain perfusion defects are evaluated using radionuclear medicine image (brain Tc-99m scan) 24-72 hours post therapy and 90 days
5. Adverse event rate is measured through patient interviews and reviewing medical records at 5 years

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Aged between 45 and 80 years
2. Chronic ischemic stroke (onset more than 6 months ago) over middle cerebral artery territory (NIHSS score 9-16)
3. Not suitable for surgery or carotid artery stenting

Participant type


Age group




Target number of participants

10 patients

Participant exclusion criteria

1. Age less than 45 years old or more than 80 years old
2. Patients received t-PA and anticoagulation
3. Non-middle cerebral artery territory stroke or hemorrhagic stroke
4. Pregnant women
5. Patients with adventitious agents (like HIV virus)
6. Myocardial infarction (MI) within 3 months
7. Severe aortic stenosis or mitral stenosis
8. Congestive heart failure, New York Heart Association functional class (NYHA Fc.)IV
9. Malignancy or other severe disease with life span less than one year
10. Chronic kidney disease with CCr<20ml/min and end stage renal disease
11. Join other clinical trials
12. Patients can not receive regular follow-up
13. Other brain disease (tumor, degenerative disease, infective disease)

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Kaohsiung Chang Gung Memorial Hospital
123, Ta Pei Road Niao Sung District

Sponsor information


National Science Council

Sponsor details

No. 106 HoPing E. Road Sec.2
+886 2 2737 7992

Sponsor type




Funder type


Funder name

National Science Council

Alternative name(s)

National Science Council, Taiwan, National Science Council of Taiwan, NSC

Funding Body Type

government organisation

Funding Body Subtype

National government



Results and Publications

Publication and dissemination plan

Planned publication in a peer reviewed journal.

Intention to publish date


Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

26/02/2019: Internal review.